ClinicalTrials.gg
CompletedNCT02202187Updated Jun 12, 2017

A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers

A Phase 1 interventional study of GSK2140944 and Placebo in Infections, Respiratory Tract, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-12.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Sep 2011, registered Mar 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Respiratory Tract Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Respiratory Tract Infections · GlaxoSmithKline.

Enrollment
8th of 19
48 · median 46
Started
2011
with 4 others
Phase 1
14 of 21
none open now
Registered
6th of 21
by date

Among the 21 studies in Respiratory Tract Infections by GlaxoSmithKline, this one is the 8th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2011, is one of 14 in phase 1, and was the 6th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

None of the 21 studies in Respiratory Tract Infections by GlaxoSmithKline is open now. The open studies under Respiratory Tract Infections, anywhere →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Respiratory Tract Infections by GlaxoSmithKline as a file.
02

Study summary

GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens associated with respiratory tract, skin and soft tissue infections including isolates resistant to existing classes of antimicrobials. This is a First Time in Human (FTIH) study to assess the safety, tolerability, and pharmacokinetics of single oral doses of GSK2140944 in healthy volunteers. This study will be a single-blind, randomized, placebo-controlled, dose-rising study in healthy subjects. The proposed single doses will range from 100 mg to 3000 mg.

Read the detailed description

GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics which is being developed for treatment of Gram positive [including methicillin resistant Staphylococcus aureus (MRSA)] and Gram-negative pathogens associated with respiratory tract and skin and soft tissue infections including isolates resistant to existing classes of antimicrobials.

Study BTZ114595 will be the first administration of GSK2140944 in humans. This study will examine the safety, tolerability, and pharmacokinetics of escalating single oral doses of GSK2140944. The predicted clinical target for efficacy, based on preclinical efficacy models, is an AUC(0-24) of 16-30 μg.h/mL. This study aims to explore the safety and tolerability at and above target exposures in order to establish a therapeutic window for this compound.

This study will investigate the safety, tolerability, and pharmacokinetics of escalating single oral doses of GSK2140944.

This will be a randomized, placebo-controlled, single-blind study to determine safety, tolerability, and single dose pharmacokinetic (PK) profile of GSK2140944 in healthy subjects.

The projected single escalating doses of GSK2140944 will range from a starting dose of 100 mg to a maximum dose of 3000 mg. The current plan is to administer the study drug after an overnight fast, but based on emerging PK and safety data, it may be necessary to administer the study drug under fed state to better understand safety, tolerability or PK of GSK2140944. Any decision to remove or modify fasting requirements will be made by the GSK Study Team and the investigator based on joint review of the emerging safety, tolerability and preliminary pharmacokinetic data from prior dose-levels.

03

Conditions studied

  • Infections, Respiratory Tract
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • , ALT, alkaline phosphatase and ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Male or female ranging from 18 to 60 years of age, at the time of signing the . Female subject must be of non- defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol \< 40 pg/mL (\<147 pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the methods in Section 8.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
  • Body weight ≥ 50 kg and within the range 19 - 31 kg/m2, inclusive.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • \< 450 msec, or QTc \< 480 msec in subjects with Bundle Branch Block., at screening.

Exclusion criteria

Exclusion Criteria:

  • Any central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such conditions that, in the opinion of the investigator may place the subject at an unacceptable risk as a participant in this trial or may interfere with the absorption, distribution, metabolism or excretion of drugs.
  • A positive urine test for drugs of abuse or alcohol (or alcohol breath test) at screening.
  • A screening urinalysis positive for protein or glucose (greater than "trace" findings of protein or glucose).
  • Positive for (HIV) antibody, virus surface antigen, or virus antibody at screening.
  • History of drug abuse within 6 months of the study.
  • History of smoking or use of nicotine containing products within 3 months of screening, or a positive urine cotinine indicative of smoking at screening.
  • History of regular alcohol consumption exceeding an average weekly intake of greater than or equal to 21 units for men/14 units for women or an average daily intake of greater than or equal to 3 units for men/2 units for women. One unit is equivalent to a 285 mL glass of full strength beer or 425 mL schooner of light beer or 1 (30 mL) measure of spirits or 1 glass (100 mL) of wine.
  • The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.
  • Use of prescription or non-prescription drugs, including vitamins above the recommended daily intake (National Health and Medical Research Council in Australia guideline), herbal and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, or use of St. John's Wort within 14 days prior to the first dose of study medication. By exception, the volunteer may take paracetamol or acetaminophen (≤ 2 grams/day) or ibuprofen (1600 mg/day) up to 48 hours prior to the first dose of study medication. However, the investigator and study team can review medication use on a case by case basis to determine if its use would compromise subject safety or interfere with study procedures or data interpretation.
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice, pummelos, exotic citrus fruits or grapefruit hybrids or fruit juices containing such products for 7 days prior to administration of study medication.
  • Donation of blood in excess of 550 mL within 12 weeks prior to dosing.
  • An unwillingness of male subjects to abstain from sexual intercourse with pregnant or lactating women, or an unwillingness of male subjects to use a condom and spermicide, in addition to having their female partner use another form of such as an IUD, diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants or a tubal ligation, if engaging in sexual intercourse with a female partner who could become pregnant. This criterion must be followed from the time of study medication administration and until 84 days after study medication administration.
  • History of sensitivity to any of the study medications or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia (if the clinical research unit uses heparin to maintain intravenous cannula patency).
  • An unwillingness to comply with lifestyle and/or dietary restrictions as described in Section 8.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    GSK2140944

    Dose range 100mg to 3000mg single dose

    Drug: GSK2140944

  • Placebo comparator
    Matching Placebo

    Placebo

    Other: Placebo

Interventions

  • Investigational Study Drug

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. GSK2140944 clinical safety data assessed as change from baseline in 12-lead ECG

    12-lead ECGs will be obtained at each timepoint using an ECG machine, after the subject has rested in the supine position for at least 10 minutes

    Time frame: Day 1, Day 2, Day 3 and at the Follow-up visit

  2. GSK2140944 clinical safety data from dual-lead cardiac monitoring

    Continuous dual-lead cardiac monitoring will be obtained at each timepoints using an ECG machine

    Time frame: Day -1, Day 1

  3. GSK2140944 clinical safety data assessed as change from baseline in clinical laboratory tests

    Clinical laboratory assessments will include hematology, clinical chemistry, routine urinalysis and additional parameters

    Time frame: Day -1, Day 2, Day 3 and the Follow-up visit

  4. GSK2140944 clinical safety data assessed as by number of adverse events (AE)

    Safety and tolerability parameters will include recording of AEs, throughout the study

    Time frame: Up to the Follow-up visit

  5. GSK2140944 clinical safety data assessed as change from baseline in blood pressure

    Vital sign measurements will include systolic and diastolic blood pressure

    Time frame: Day -1, Day 1, Day 2, Day 3 and the Follow-up visit

  6. GSK2140944 clinical safety data assessed as change from baseline in heart rate

    Vital sign measurements will include pulse rate

    Time frame: Day -1, Day 1, Day 2, Day 3 and the Follow-up visit

Secondary outcomes

  1. Pharmacokinetic parameter: AUC(0-t) following single dose of GSK2140944

    Pharmacokinetic data will include area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC(0-t)) following single dose of GSK2140944

    Time frame: Up to Day 4

  2. Pharmacokinetic parameter: AUC(0-infinity) following single dose of GSK2140944

    Pharmacokinetic data will include area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity)) following single dose of GSK2140944

    Time frame: Up to Day 4

  3. Pharmacokinetic parameter: Cmax following single dose of GSK2140944

    Pharmacokinetic data will include maximum observed concentration (Cmax) following single dose of GSK2140944

    Time frame: Up to Day 4

  4. Pharmacokinetic parameter: tmax following single dose of GSK2140944

    Pharmacokinetic data will include time of occurrence of Cmax (tmax) following single dose of GSK2140944

    Time frame: Up to Day 4

  5. Pharmacokinetic parameter: t1/2 following single dose of GSK2140944

    Pharmacokinetic data will include terminal phase half-life (t1/2) following single dose of GSK2140944

    Time frame: Up to Day 4

  6. To assess preliminary dose proportionality using PK parameter AUC(0-infinity) following single dose of GSK2140944

    Preliminary dose proportionality will be assessed using PK parameter (AUC(0-infinity)) following single dose of GSK2140944

    Time frame: Up to Day 4

  7. To assess preliminary dose proportionality using PK parameter Cmax following single dose of GSK2140944

    Preliminary dose proportionality will be assessed using PK parameter Cmax following single dose of GSK2140944

    Time frame: Up to Day 4

  8. Pharmacokinetic parameter: (Ae) following single dose of GSK2140944

    Pharmacokinetic data will include urinary recovery of unchanged drug (Ae) following single dose of GSK2140944

    Time frame: Up to Day 4

  9. Pharmacokinetic parameter: (CLr) following single dose of GSK2140944

    Pharmacokinetic data will include renal clearance (CLr) following single dose of GSK2140944

    Time frame: Up to Day 4

07

Study locations

1 site
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2011 to primary completion in Feb 2012, 4 months.

Of 26 industry-sponsored phase 1 interventional studies under Respiratory Tract Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 4 months is below that.

Counting every sponsor, half of 35 studies reached it within 8 months; a quarter within 1 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2012
First posted
Jul 28, 2014
StartActual
Sep 26, 2011
Primary completionActual
Feb 15, 2012
CompletionActual
Feb 15, 2012
Last update
Jun 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02202187
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 28, 2014
Start date
Sep 26, 2011
Primary completion
Feb 15, 2012
Completion
Feb 15, 2012
Last update
Jun 12, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion